Skip to content

Study · Randomized controlled trial · n = 60 · 2019

10 results

Continuous subcutaneous insulin infusion combined with liraglutide reduced glycemic variability and oxidative stress in type 2 diabetes mellitus: a study based on the flash glucose monitoring system.

Li LQ, Yao MY, Ma JX, Xue P, Li YK

Endocrine journal27 Jun 2019Cited by 16 (Europe PMC)

PMID31243192 (opens in a new tab)DOI10.1507/endocrj.ej19-0016 (opens in a new tab)PepBankPUB-31243192
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, estimated HbA1c fell in both groups, especially in the CSII plus liraglutide group.

    In plain wordsIn adults with new type 2 diabetes, estimated HbA1c fell in both groups, and fell most with insulin pump plus liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseEstimated HbA1c
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The estimated HbA1c and MBG decreased in both groups, especially the CSII + liraglutide group.
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, mean blood glucose fell in both groups, especially in the CSII plus liraglutide group.

    In plain wordsIn adults with new type 2 diabetes, average blood glucose fell in both groups, and fell most with insulin pump plus liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean blood glucose concentration
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The estimated HbA1c and MBG decreased in both groups, especially the CSII + liraglutide group.
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the SD of glucose was lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, glucose swings measured by SD were smaller with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseStandard deviation of mean glucose
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SD, IQR, LAGE, and MODD were significantly lower in the CSII + liraglutide group than in the CSII group (all p < 0.05)
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the glucose IQR was lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, glucose IQR was lower with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseInterquartile range of glucose
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SD, IQR, LAGE, and MODD were significantly lower in the CSII + liraglutide group than in the CSII group (all p < 0.05)
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, LAGE was lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, the largest glucose swing was smaller with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseLargest amplitude of glycemic excursions (LAGE)
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SD, IQR, LAGE, and MODD were significantly lower in the CSII + liraglutide group than in the CSII group (all p < 0.05)
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, MODD was lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, day-to-day glucose difference was smaller with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean of daily difference (MODD)
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SD, IQR, LAGE, and MODD were significantly lower in the CSII + liraglutide group than in the CSII group (all p < 0.05)
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, the coefficient of variation of glucose did not differ between CSII plus liraglutide and CSII alone.

    In plain wordsIn adults with new type 2 diabetes, glucose CV did not differ between insulin pump plus liraglutide and the pump alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeCoefficient of variation of glucose
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    there was no difference in CV or MAGE (p > 0.05).
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, MAGE did not differ between CSII plus liraglutide and CSII alone.

    In plain wordsIn adults with new type 2 diabetes, MAGE did not differ between insulin pump plus liraglutide and the pump alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeMean amplitude of glycemic excursions (MAGE)
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    there was no difference in CV or MAGE (p > 0.05).
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 4-HNE levels were lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, an oxidative stress marker (4-HNE) was lower with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    Decrease4-hydroxynonenal (4-HNE) level
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Oxidative stress · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the 4-HNE and 8-OHdG levels were significantly lower in the CSII + liraglutide group (p < 0.05).
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with newly diagnosed type 2 diabetes, 8-OHdG levels were lower with CSII plus liraglutide than with CSII alone.

    In plain wordsIn adults with new type 2 diabetes, an oxidative stress marker (8-OHdG) was lower with insulin pump plus liraglutide than with the pump alone.

    Peptide
    Liraglutide
    Outcome
    Decrease8-hydroxydeoxyguanosine (8-OHdG) level
    Study

    n = 60

    Comparator
    CSII alone
    Outcome group
    Oxidative stress · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Similarly, the 4-HNE and 8-OHdG levels were significantly lower in the CSII + liraglutide group (p < 0.05).
    2 context sentences
    Summary · context
    This was an open-label, randomized study that was conducted in 60 newly diagnosed T2DM patients.
    Summary · context
    The patients were randomized to receive either CSII (n = 30) or CSII + liraglutide (n = 30).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.